Genetic Technologies Ltd (GENE) - Total Liabilities
Based on the latest financial reports, Genetic Technologies Ltd (GENE) has total liabilities worth $4.36 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genetic Technologies Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Genetic Technologies Ltd to evaluate short-term liquidity relative to the company's equity base.
Genetic Technologies Ltd Competitors by Total Liabilities
The table below lists competitors of Genetic Technologies Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avira Resources Ltd
AU:AVW
|
Australia | AU$114.47K |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
Korea | ₩81.45 Billion |
|
Capstone Holding Corp. Common Stock
NASDAQ:CAPS
|
USA | $42.57 Million |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
Indonesia | Rp54.14 Billion |
|
ICZOOM Group Inc. Class A Ordinary Shares
NASDAQ:IZM
|
USA | $25.82 Million |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
USA | $1.13 Billion |
|
Aeeris Ltd
AU:AER
|
Australia | AU$891.79K |
|
Ganga Forging Limited
NSE:GANGAFORGE
|
India | Rs302.43 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Genetic Technologies Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Genetic Technologies Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genetic Technologies Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genetic Technologies Ltd (2000–2024)
The table below shows the annual total liabilities of Genetic Technologies Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $4.36 Million | +17.93% |
| 2023-06-30 | $3.69 Million | -15.49% |
| 2022-06-30 | $4.37 Million | +203.80% |
| 2021-06-30 | $1.44 Million | -12.30% |
| 2020-06-30 | $1.64 Million | +9.81% |
| 2019-06-30 | $1.49 Million | +2.73% |
| 2018-06-30 | $1.45 Million | -4.91% |
| 2017-06-30 | $1.53 Million | +8.73% |
| 2016-06-30 | $1.41 Million | -20.11% |
| 2015-06-30 | $1.76 Million | -64.08% |
| 2014-06-30 | $4.90 Million | +91.38% |
| 2013-06-30 | $2.56 Million | +25.61% |
| 2012-06-30 | $2.04 Million | -3.28% |
| 2011-06-30 | $2.11 Million | -17.70% |
| 2010-06-30 | $2.56 Million | -46.51% |
| 2009-06-30 | $4.79 Million | +44.42% |
| 2008-06-30 | $3.32 Million | -18.12% |
| 2007-06-30 | $4.05 Million | -3.01% |
| 2006-06-30 | $4.18 Million | -35.85% |
| 2005-06-30 | $6.51 Million | +22.35% |
| 2004-06-30 | $5.32 Million | +79.25% |
| 2003-06-30 | $2.97 Million | +59.17% |
| 2002-06-30 | $1.86 Million | +15.24% |
| 2001-06-30 | $1.62 Million | +27.42% |
| 2000-06-30 | $1.27 Million | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more